| Lipid-lowering interventions in managed care settings. | |
| | |
MedLine Citation:
|
PMID: 11311194 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Effective screening, treatment, and follow-up of patients with elevated serum lipid levels is important because of the very strong association between this condition and coronary heart disease (CHD). Screening of patients with and without CHD for hyperlipidemia is not generally carried out properly by managed care organizations (MCOs) or in other settings. Primary and secondary prevention are inadequate in most patients with this condition; even in patients who are treated, lipid-lowering therapy is often not used to its full potential. These trends have been confirmed by findings in the first of a three-phase hyperlipidemia outcomes management program carried out at 27 US MCOs. The efficacy of lipid-lowering therapy can be enhanced by physician education and comprehensive, integrated quality improvement programs. The cost-effectiveness of such treatment can be improved by individualizing both drug and dose to achieve National Cholesterol Education Program goals at the lowest drug acquisition cost. The quality improvement program described and others like it have the potential to reduce the morbidity and mortality associated with CHD while decreasing the huge economic burden associated with this disease. Several such programs have been undertaken at MCOs, some with more success than others. Interventions and assessments of the type planned in phases 2 and 3 of this program can help to reduce the cost of lipid-lowering therapy without compromising cholesterol goal achievement. |
| | |
Authors:
|
J Fox; K Jones |
Related Documents
:
|
18694194 - Qualitative assessment of diabetes-star: a patient portal with disease management funct... 10424934 - Development of a statewide protocol for the prehospital identification of dnr patients ... 20546374 - Effectiveness of an interventional program to improve blood pressure control in hyperte... 19520614 - Learning style and learning needs of heart failure patients (the need2know-hf patient s... 3610894 - Field replication of classwide peer tutoring. 3274044 - Unfavourable outcomes of drug therapy--subjective probability versus confidence intervals. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American journal of medicine Volume: 110 Suppl 6A ISSN: 0002-9343 ISO Abbreviation: Am. J. Med. Publication Date: 2001 Apr |
Date Detail:
|
Created Date: 2001-04-20 Completed Date: 2001-06-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0267200 Medline TA: Am J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 24S-30S Citation Subset: AIM; IM |
Affiliation:
|
M-Plan, Indianapolis, Indiana, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
economics,
therapeutic use* Cholesterol, LDL / blood Coronary Disease / drug therapy, economics, prevention & control* Disease Management* Health Maintenance Organizations Humans Hyperlipidemias / drug therapy*, economics Managed Care Programs* Outcome Assessment (Health Care) Primary Prevention Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Cholesterol, LDL |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans.
Next Document: A comparison of human dental plaque microcosm biofilms grown in an undefined medium and a chemically...